Phase III trial of Tecentriq combo in early liver cancer meets primary goal

The pivotal Phase III IMbrave050 study, which investigated PD-L1 inhibitor Tecentriq (atezolizumab) plus anti-VEGF antibody Avastin (bevacizumab) in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence following surgery, met primary endpoint of recurrence-free survival at the prespecified interim analysis, according to Swiss pharma giant Roche (ROG: SIX).

The Tecentriq combination showed a statistically-significant improvement in RFS in the intention-to-treat population of HCC patients who have an increased risk of recurrence following resection or ablation with curative intent, compared with active surveillance.

Overall survival data were immature at the time of interim analysis and follow-up will continue to the next analysis. Safety for Tecentriq and Avastin was consistent with the known safety profile of each therapeutic agent and with the underlying disease.